Alpha 2.0
Login Register
» Authors » Andrea Ardizzoni

Andrea Ardizzoni

Explore the profile of Andrea Ardizzoni including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 340
Citations 5545
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Microbiology
Top 10 Co-Authors
Marcello Tiseo
Francesco Gelsomino
Michelangelo Fiorentino
Francesco Massari
Francesca Sperandi
Elisabetta Blasi
Alessandro Di Federico
Barbara Melotti
Pier Giorgio Petronini
Andrea Cavazzoni
Published In
Lung Cancer
J Thorac Oncol
J Clin Oncol
Tumori
Cancers (Basel)
Affiliations
Soon will be listed here.
Recent Articles
1.
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report
De Giglio A, Zacchini F, Venturi G, Di Federico A, Parisi C, DallOlio F, et al.
J Liq Biopsy . 2025 Mar; 6:100161. PMID: 40027319
Background: The frontline management of non-oncogene addicted non-small cell lung cancer (NSCLC) involves immune-checkpoint inhibitors (ICI) alone or combined with chemotherapy (CT-ICI). The dynamic landscape of KRAS-positive NSCLC presents a...
2.
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience
Parisi C, Benitez J, Lecourt H, DallOlio F, Aldea M, Blanc-Durand F, et al.
J Liq Biopsy . 2025 Mar; 6:100164. PMID: 40027306
Importance: Deregulation of anaplastic lymphoma kinase (ALK) occurs in 3-7% of advanced NSCLC mainly because of chromosomic rearrangements at the ALK locus. Next to its oncogenic function, ALK chimeric oncoprotein...
3.
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
de Marinis F, Ardizzoni A, Attili I, Bonanno L, Bria E, Cortinovis D, et al.
Curr Oncol . 2025 Feb; 32(2). PMID: 39996910
Background: Immunotherapy (IO)-based strategies have been demonstrated to significantly prolong survival in the perioperative setting of non-oncogene-addicted non-small cell lung cancer (NSCLC). The adoption of such strategies in clinical practice...
4.
Modulation of -Induced Immune Response in Vaginal Epithelial Cells by Garcinoic Acid
Sabbatini S, Zatini L, Narducci E, Rosati L, Ardizzoni A, Mencacci A, et al.
Microorganisms . 2025 Jan; 12(12. PMID: 39770658
Vulvovaginal candidiasis (VVC) is a prevalent women's infection characterized by excessive inflammation and damage of the vaginal epithelium that, in its recurrent form (RVVC), causes more than three symptomatic episodes...
5.
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
Angelicola S, Giunchi F, Ruzzi F, Frascino M, Pitzalis M, Scalambra L, et al.
J Transl Med . 2025 Jan; 23(1):2. PMID: 39748404
Background: Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death worldwide. Although immune checkpoint inhibitors (ICIs) have shown remarkable clinical efficacy, they can also induce a paradoxical...
6.
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
De Giglio A, de Biase D, Favorito V, Maloberti T, Di Federico A, Zacchini F, et al.
Lung Cancer . 2024 Dec; 199:108058. PMID: 39709652
Background: The upfront treatment of non-oncogene-addicted NSCLC relies on immunotherapy alone (ICI) or in combination with chemotherapy (CT-ICI). Genomic aberrations such as KRAS, TP53, KEAP1, SMARCA4, or STK11 may impact...
7.
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC...
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis D, et al.
Lung Cancer . 2024 Dec; 199:108059. PMID: 39700681
Background: As for squamous (Sq)-NSCLC, Checkmate-017 trial showed a significant overall survival (OS) improvement in favor of Nivolumab (Nivo) over Docetaxel in 2nd-line. We hypothesized that anticipating Nivo use, as...
8.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring Class 3 Mutations
Di Federico A, Angelicola S, Frascino M, Siracusa I, Bisanti B, Ruzzi F, et al.
JCO Precis Oncol . 2024 Dec; 8:e2400240. PMID: 39637338
Purpose: Patients with tumors harboring class 3 mutations lack targeted therapies. These mutations are characterized by low/absent BRAF kinase domain activation and are believed to amplify already active RAS signaling,...
9.
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
DallOlio F, Zrafi W, Roelants V, Ambrosini V, Fourquet A, Mitea C, et al.
Clin Cancer Res . 2024 Oct; 31(2):352-364. PMID: 39437011
Purpose: This study aimed to explore metabolic tumor volume (MTV) as assessed by 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET/CT) and understand its biological meaning in patients with non-small cell lung...
10.
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy
De Giglio A, Leonetti A, Comito F, Filippini D, Mollica V, Rihawi K, et al.
Cancer Immunol Immunother . 2024 Oct; 73(12):246. PMID: 39358642
Background: Immune checkpoint inhibitors (ICIs) are standard treatments for advanced solid cancers. Resistance to ICIs, both primary and secondary, poses challenges, with early mortality (EM) within 30-90 days indicating a...